BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 2009;9:511-23. [PMID: 19374604 DOI: 10.1586/era.09.7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Jin Y, Peng D, Shen Y, Xu M, Liang Y, Xiao B, Lu J. MicroRNA-376c Inhibits Cell Proliferation and Invasion in Osteosarcoma by Targeting to Transforming Growth Factor-Alpha. DNA and Cell Biology 2013;32:302-9. [DOI: 10.1089/dna.2013.1977] [Cited by in F6Publishing: 31] [Reference Citation Analysis]
2 Ruan W, Wang P, Feng S, Xue Y, Li Y. Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiomotin gene expression in human osteosarcoma cells. Tumour Biol 2016;37:4065-73. [PMID: 26486328 DOI: 10.1007/s13277-015-4256-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 9.7] [Reference Citation Analysis]
3 Zheng C, You W, Wan P, Jiang X, Chen J, Zheng Y, Li W, Tan J, Zhang S. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11004. [PMID: 29923984 DOI: 10.1097/MD.0000000000011004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
4 Lerner A, Antman KH. Primary and Metastatic Malignant Bone Lesions. Goldman's Cecil Medicine. Elsevier; 2012. pp. 1325-7. [DOI: 10.1016/b978-1-4377-1604-7.00208-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Zhang Y, Yang J, Zhao N, Wang C, Kamar S, Zhou Y, He Z, Yang J, Sun B, Shi X, Han L, Yang Z. Progress in the chemotherapeutic treatment of osteosarcoma. Oncol Lett 2018;16:6228-37. [PMID: 30405759 DOI: 10.3892/ol.2018.9434] [Cited by in Crossref: 22] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
6 Hattinger CM, Patrizio MP, Luppi S, Serra M. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact. Int J Mol Sci 2020;21:E4659. [PMID: 32629971 DOI: 10.3390/ijms21134659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Piskun CM, Stein TJ. β-Catenin transcriptional activity is minimal in canine osteosarcoma and its targeted inhibition results in minimal changes to cell line behaviour. Vet Comp Oncol 2016;14:e4-e16. [PMID: 24256430 DOI: 10.1111/vco.12077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
8 Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 2011;11:125. [PMID: 21481226 DOI: 10.1186/1471-2407-11-125] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 5.8] [Reference Citation Analysis]
9 Fang D, Yang H, Lin J, Teng Y, Jiang Y, Chen J, Li Y. 17β-estradiol regulates cell proliferation, colony formation, migration, invasion and promotes apoptosis by upregulating miR-9 and thus degrades MALAT-1 in osteosarcoma cell MG-63 in an estrogen receptor-independent manner. Biochem Biophys Res Commun 2015;457:500-6. [PMID: 25592968 DOI: 10.1016/j.bbrc.2014.12.114] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
10 Jauregui JJ, Nadarajah V, Munn J, Pivec R, Kapadia BH, Lerman DM, Maheshwari AV. Limb Salvage Versus Amputation in Conventional Appendicular Osteosarcoma: a Systematic Review. Indian J Surg Oncol 2018;9:232-40. [PMID: 29887707 DOI: 10.1007/s13193-018-0725-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
11 Duffaud F, Egerer G, Ferrari S, Rassam H, Boecker U, Bui-Nguyen B. A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma. Eur J Cancer 2012;48:564-70. [PMID: 22243773 DOI: 10.1016/j.ejca.2011.12.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
12 Chiu YJ, Hour MJ, Jin YA, Lu CC, Tsai FJ, Chen TL, Ma H, Juan YN, Yang JS. Disruption of IGF‑1R signaling by a novel quinazoline derivative, HMJ‑30, inhibits invasiveness and reverses epithelial-mesenchymal transition in osteosarcoma U‑2 OS cells. Int J Oncol 2018;52:1465-78. [PMID: 29568964 DOI: 10.3892/ijo.2018.4325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H, Hornicek F. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther. 2011;10:1337-1345. [PMID: 21666078 DOI: 10.1158/1535-7163.mct-11-0096] [Cited by in Crossref: 178] [Cited by in F6Publishing: 107] [Article Influence: 16.2] [Reference Citation Analysis]
14 Duan L, Perez RE, Hansen M, Gitelis S, Maki CG. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther 2014;15:1600-12. [PMID: 25482935 DOI: 10.4161/15384047.2014.961876] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
15 Li C, Cheng Q, Liu J, Wang B, Chen D, Liu Y. Potent growth-inhibitory effect of TRAIL therapy mediated by double-regulated oncolytic adenovirus on osteosarcoma. Mol Cell Biochem 2012;364:337-44. [PMID: 22354724 DOI: 10.1007/s11010-012-1235-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
16 Jeon DG, Song WS. How can survival be improved in localized osteosarcoma? Expert Rev Anticancer Ther 2010;10:1313-25. [PMID: 20735316 DOI: 10.1586/era.10.79] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
17 Choy E, Hornicek F, MacConaill L, Harmon D, Tariq Z, Garraway L, Duan Z. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 2012;118:2905-14. [PMID: 22006429 DOI: 10.1002/cncr.26617] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
18 Niswander LM, Kim SY. Stratifying osteosarcoma: minimizing and maximizing therapy. Curr Oncol Rep 2010;12:266-70. [PMID: 20473649 DOI: 10.1007/s11912-010-0106-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
19 Zhang Y, Hu H, Song L, Cai L, Wei R, Jin W. Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation. Toxicol Lett 2013;222:1-9. [PMID: 23845851 DOI: 10.1016/j.toxlet.2013.06.242] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
20 Melim C, Jarak I, Veiga F, Figueiras A. The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease. 3 Biotech 2020;10:147. [PMID: 32181109 DOI: 10.1007/s13205-020-2142-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Xie L, Ji T, Guo W. Anti-angiogenesis target therapy for advanced osteosarcoma (Review). Oncol Rep 2017;38:625-36. [PMID: 28656259 DOI: 10.3892/or.2017.5735] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
22 Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2014;2:690-8. [PMID: 24866169 DOI: 10.1158/2326-6066.CIR-13-0224] [Cited by in Crossref: 114] [Cited by in F6Publishing: 80] [Article Influence: 14.3] [Reference Citation Analysis]
23 Ning L, Wan S, Jie Z, Xie Z, Li X, Pan X, Wan X, Chen W, Huang H, Wang J, Qin A, Fan S, Zhao X. Lycorine Induces Apoptosis and G1 Phase Arrest Through ROS/p38 MAPK Signaling Pathway in Human Osteosarcoma Cells In Vitro and In Vivo. Spine (Phila Pa 1976) 2020;45:E126-39. [PMID: 31464976 DOI: 10.1097/BRS.0000000000003217] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
24 Rivera-Valentin RK, Zhu L, Hughes DP. Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy. Paediatr Drugs 2015;17:257-71. [PMID: 26002157 DOI: 10.1007/s40272-015-0134-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
25 Hu B, Lv X, Gao F, Chen S, Wang S, Qing X, Liu J, Wang B, Shao Z. Downregulation of DEPTOR inhibits the proliferation, migration, and survival of osteosarcoma through PI3K/Akt/mTOR pathway. Onco Targets Ther 2017;10:4379-91. [PMID: 28932123 DOI: 10.2147/OTT.S143518] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
26 Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol 2013;5:147-62. [PMID: 23700373 DOI: 10.2147/CLEP.S28390] [Cited by in Crossref: 16] [Cited by in F6Publishing: 55] [Article Influence: 1.8] [Reference Citation Analysis]
27 Endo-Munoz L, Evdokiou A, Saunders NA. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochim Biophys Acta 2012;1826:434-42. [PMID: 22846337 DOI: 10.1016/j.bbcan.2012.07.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 47] [Article Influence: 2.1] [Reference Citation Analysis]
28 Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, Ferrari S, Aglietta M. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012;23:508-16. [PMID: 21527590 DOI: 10.1093/annonc/mdr151] [Cited by in Crossref: 195] [Cited by in F6Publishing: 181] [Article Influence: 17.7] [Reference Citation Analysis]
29 Gorlick R, Khanna C. Osteosarcoma. J Bone Miner Res 2010;25:683-91. [PMID: 20205169 DOI: 10.1002/jbmr.77] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 8.8] [Reference Citation Analysis]
30 Marchandet L, Lallier M, Charrier C, Baud'huin M, Ory B, Lamoureux F. Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers (Basel) 2021;13:683. [PMID: 33567616 DOI: 10.3390/cancers13040683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
31 Morello E, Martano M, Buracco P. Biology, diagnosis and treatment of canine appendicular osteosarcoma: Similarities and differences with human osteosarcoma. The Veterinary Journal 2011;189:268-77. [DOI: 10.1016/j.tvjl.2010.08.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 7.3] [Reference Citation Analysis]
32 Xu M, Xu CX, Bi WZ, Song ZG, Jia JP, Chai W, Zhang LH, Wang Y. Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone. 2013;57:111-115. [PMID: 23912049 DOI: 10.1016/j.bone.2013.07.035] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
33 Wang TX, Tan WL, Huang JC, Cui ZF, Liang RD, Li QC, Lu H. Identification of aberrantly methylated differentially expressed genes targeted by differentially expressed miRNA in osteosarcoma. Ann Transl Med 2020;8:373. [PMID: 32355817 DOI: 10.21037/atm.2020.02.74] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, Araujo DM, Chen K, Zhang W. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 2011;117:4925-38. [PMID: 21495021 DOI: 10.1002/cncr.26116] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 6.0] [Reference Citation Analysis]
35 Svoboda M, Hamilton G, Thalhammer T. Steroid hormone metabolizing enzymes in benign and malignant human bone tumors. Expert Opin Drug Metab Toxicol 2010;6:427-37. [PMID: 20102288 DOI: 10.1517/17425251003592129] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
36 Zhang Y, He Z, Duan Y, Wang C, Kamar S, Shi X, Yang J, Yang J, Zhao N, Han L, Yang Y, Yang Z. Does intensified chemotherapy increase survival outcomes of osteosarcoma patients? A meta-analysis. J Bone Oncol 2018;12:54-60. [PMID: 29963367 DOI: 10.1016/j.jbo.2018.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
37 Almeida JR, Mendes B, Lancellotti M, Franchi GC, Passos Ó, Ramos MJ, Fernandes PA, Alves C, Vale N, Gomes P, da Silva SL. Lessons from a Single Amino Acid Substitution: Anticancer and Antibacterial Properties of Two Phospholipase A2-Derived Peptides. CIMB 2022;44:46-62. [DOI: 10.3390/cimb44010004] [Reference Citation Analysis]
38 Qin YG, Zhu LY, Wang CY, Zhang BY, Wang QY, Li RY, Liu Z. Glycol chitosan incorporated retinoic acid chlorochalcone (RACC) nanoparticles in the treatment of Osteosarcoma. Lipids Health Dis 2015;14:70. [PMID: 26170203 DOI: 10.1186/s12944-015-0068-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
39 Serra M, Hattinger CM. The pharmacogenomics of osteosarcoma. Pharmacogenomics J 2017;17:11-20. [PMID: 27241064 DOI: 10.1038/tpj.2016.45] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
40 Lézot F, Chesneau J, Navet B, Gobin B, Amiaud J, Choi Y, Yagita H, Castaneda B, Berdal A, Mueller CG, Rédini F, Heymann D. Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect with zoledronic acid. Bone 2015;73:51-9. [PMID: 25532478 DOI: 10.1016/j.bone.2014.12.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
41 Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Huh W, Sutphin R, Vyas YM, Shen V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer 2014;61:238-44. [PMID: 23997016 DOI: 10.1002/pbc.24686] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
42 Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 2010;15:615-34. [PMID: 20690888 DOI: 10.1517/14728214.2010.505603] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
43 Chiu YJ, Hour MJ, Lu CC, Chung JG, Kuo SC, Huang WW, Chen HJ, Jin YA, Yang JS. Novel quinazoline HMJ-30 induces U-2 OS human osteogenic sarcoma cell apoptosis through induction of oxidative stress and up-regulation of ATM/p53 signaling pathway. J Orthop Res 2011;29:1448-56. [PMID: 21425328 DOI: 10.1002/jor.21398] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
44 Hattinger CM, Fanelli M, Tavanti E, Vella S, Ferrari S, Picci P, Serra M. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs 2015;20:495-514. [PMID: 26021401 DOI: 10.1517/14728214.2015.1051965] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
45 Hattinger CM, Tavanti E, Fanelli M, Vella S, Picci P, Serra M. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. Expert Opin Drug Metab Toxicol 2017;13:245-57. [PMID: 27758143 DOI: 10.1080/17425255.2017.1246532] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
46 Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther 2016;16:543-56. [PMID: 26999418 DOI: 10.1586/14737140.2016.1168697] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 15.2] [Reference Citation Analysis]
47 Dai X, Ma W, He X, Jha RK. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit 2011;17:RA177-190. [PMID: 21804475 DOI: 10.12659/msm.881893] [Cited by in Crossref: 56] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
48 Mitsunaga MM, Bateni C, Bindra J. Venous tumor thrombus from a pelvic osteosarcoma. Radiol Case Rep 2013;8:864. [PMID: 27330641 DOI: 10.2484/rcr.v8i3.864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
49 Mobasheri A, Cassidy JP. Biomarkers in veterinary medicine: Towards targeted, individualised therapies for companion animals. Vet J 2010;185:1-3. [PMID: 20541693 DOI: 10.1016/j.tvjl.2010.04.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
50 Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) 2013;5:591-616. [PMID: 24216993 DOI: 10.3390/cancers5020591] [Cited by in Crossref: 131] [Cited by in F6Publishing: 124] [Article Influence: 14.6] [Reference Citation Analysis]
51 Krzyzankova M, Chovanova S, Chlapek P, Radsetoulal M, Neradil J, Zitterbart K, Sterba J, Veselska R. LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines. Tumor Biol 2014;35:7617-27. [DOI: 10.1007/s13277-014-2019-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
52 Duffaud F. Role of TKI for Metastatic Osteogenic Sarcoma. Curr Treat Options Oncol 2020;21:65. [PMID: 32601895 DOI: 10.1007/s11864-020-00760-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
53 Sharili AS, Allen S, Smith K, Price J, McGonnell IM. Snail2 promotes osteosarcoma cell motility through remodelling of the actin cytoskeleton and regulates tumor development. Cancer Lett 2013;333:170-9. [PMID: 23352643 DOI: 10.1016/j.canlet.2013.01.027] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
54 Chen CC, Chueh FS, Peng SF, Huang WW, Tsai CH, Tsai FJ, Huang CY, Tang CH, Yang JS, Hsu YM, Yin MC, Huang YP, Chung JG. Cantharidin decreased viable cell number in human osteosarcoma U-2 OS cells through G2/M phase arrest and induction of cell apoptosis. Biosci Biotechnol Biochem 2019;83:1912-23. [PMID: 31187696 DOI: 10.1080/09168451.2019.1627182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
55 Cao Y, Roth M, Piperdi S, Montoya K, Sowers R, Rao P, Geller D, Houghton P, Kolb EA, Gill J, Gorlick R. Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma. PLoS One 2014;9:e106249. [PMID: 25170759 DOI: 10.1371/journal.pone.0106249] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
56 Yang J, Cheng D, Zhou S, Zhu B, Hu T, Yang Q. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma. Int J Mol Sci 2015;16:28635-46. [PMID: 26633383 DOI: 10.3390/ijms161226123] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
57 Davaadelger B, Perez RE, Zhou Y, Duan L, Gitelis S, Maki CG. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther 2017;18:895-903. [PMID: 28696156 DOI: 10.1080/15384047.2017.1345397] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
58 Rauch DA, Hurchla MA, Harding JC, Deng H, Shea LK, Eagleton MC, Niewiesk S, Lairmore MD, Piwnica-Worms D, Rosol TJ, Weber JD, Ratner L, Weilbaecher KN. The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice. PLoS One 2010;5:e15755. [PMID: 21209895 DOI: 10.1371/journal.pone.0015755] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
59 Michalakis K, Bakopoulou A, Papachristou E, Vasilaki D, Tsouknidas A, Michailidis N, Johnstone E. Evaluation of the Response of HOS and Saos-2 Osteosarcoma Cell Lines When Exposed to Different Sizes and Concentrations of Silver Nanoparticles. Biomed Res Int 2021;2021:5013065. [PMID: 34938808 DOI: 10.1155/2021/5013065] [Reference Citation Analysis]